Stability and activity in sputum of G10KHc, a potent anti-pseudomonas antimicrobial peptide

Chemical Biology and Drug Design

Volumn 70, Issue 5, 2007, Pages 456-460

  Eckert, Randal ^a   Mchardy, Ian ^a   Yarbrough, Daniel K ^a   He, Jian ^a   Qi, Fengxia ^a,c   Anderson, Maxwell H ^b   Shi, Wenyuan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b C3 Jian Inc   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antimicrobial peptide; Cystic fibrosis; D amino acids; Pseudomonas; Targeted therapeutic

Indexed keywords

ANTIBIOTIC AGENT; DEOXYRIBONUCLEASE; G10KHC PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CYSTIC FIBROSIS; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; SPUTUM;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; DRUG STABILITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; PSEUDOMONAS AERUGINOSA; SPUTUM;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 35348994316     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00580.x     Document Type: Article

References (23)

1. Eckert R., Qi F., Yarbrough D.K., He J., Anderson M.H., Shi W. (2006) Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob Agents Chemother 50: 1480 1488.
2. Eckert R., Brady K.M., Greenberg E.P., Qi F., Yarbrough D.K., He J., McHardy I., Anderson M.H., Shi W. (2006) Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 50: 3833 3838.
3. Palmer K.L., Mashburn L.M., Singh P.K., Whiteley M. (2005) Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 187: 5267 5277.
4. Govan J.R., Deretic V. (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60: 539 574.
5. Zhang L., Parente J., Harris S.M., Woods D.E., Hancock R.E., Falla T.J. (2005) Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Chemother 49: 2921 2927.
6. Birrer P., McElvaney N.G., Rudeberg A., Sommer C.W., Liechti-Gallati S., Kraemer R., Hubbard R., Crystal R.G. (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150: 207 213.
7. Hunt B.E., Weber A., Berger A., Ramsey B., Smith A.L. (1995) Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 39: 34 39.
8. Kelly M.M., Leigh R., Carruthers S., Horsewood P., Gleich G.J., Hargreave F.E., Cox G. (2001) Increased detection of interleukin-5 in sputum by addition of protease inhibitors. Eur Respir J 18: 685 691.
9. Rao N.V., Wehner N.G., Marshall B.C., Gray W.R., Gray B.H., Hoidal J.R. (1991) Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 266: 9540 9548.
10. Witko-Sarsat V., Halbwachs-Mecarelli L., Schuster A., Nusbaum P., Ueki I., Canteloup S., Lenoir G., Descamps-Latscha B., Nadel J.A. (1999) Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 20: 729 736.
11. Sajjan U.S., Tran L.T., Sole N., Rovaldi C., Akiyama A., Friden P.M., Forstner J.F., Rothstein D.M. (2001) P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 45: 3437 3444.
12. Alcorn J.F., Wright J.R. (2004) Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol Chem 279: 30871 30879.
13. Britigan B.E., Hayek M.B., Doebbeling B.N., Fick R.B. Jr. (1993) Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun 61: 5049 5055.
14. Milton R.C., Milton S.C., Kent S.B. (1992) Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected]. Science 256: 1445 1448.
15. Hubbard R.C., McElvaney N.G., Birrer P., Shak S., Robinson W.W., Jolley C., Wu M., Chernick M.S., Crystal R.G. (1992) A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 326: 812 815.
16. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., Rosenstein B.J., Smith A.L., Wohl M.E. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331: 637 642.
17. McElvaney N.G., Hubbard R.C., Birrer P., Chernick M.S., Caplan D.B., Frank M.M., Crystal R.G. (1991) Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 337: 392 394.
18. Woods D.E., Cantin A., Cooley J., Kenney D.M., Remold-O'Donnell E. (2005) Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 39: 141 149.
19. Cantin A.M., Woods D.E., Cloutier D., Heroux J., Dufour E.K., Leduc R. (2002) Leukocyte elastase inhibition therapy in cystic fibrosis: role of glycosylation on the distribution of alpha-1-proteinase inhibitor in blood versus lung. J Aerosol Med 15: 141 148.
20. Martin S.L., Downey D., Bilton D., Keogan M.T., Edgar J., Elborn J.S. (2006) Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 41: 177 183.
21. Mangoni M.L., Papo N., Saugar J.M., Barra D., Shai Y., Simmaco M., Rivas L. (2006) Effect of natural l- to d-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides Bombinins H. Biochemistry 45: 4266 4276.
22. Hong S.Y., Oh J.E., Lee K.-H. (1999) Effect of -amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58: 1775 1780.
23. Chen Y., Vasil A.I., Rehaume L., Mant C.T., Burns J.L., Vasil M.L., Hancock R.E., Hodges R.S. (2006) Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem Biol Drug Des 67: 62 73.